---
title: "Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000623.SZ.md"
symbol: "000623.SZ"
name: "Jilin Aodong Pharmaceutical Group Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:50:35.703Z"
locales:
  - [en](https://longbridge.com/en/quote/000623.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000623.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000623.SZ.md)
---

# Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)

## Company Overview

Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China. It provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; production and sale of packaging materials; and information consulting and advertising design and production activities.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jlaod.com](https://www.jlaod.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.50)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 79 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.12% |  |
| Net Profit YoY | 42.60% |  |
| P/B Ratio | 0.67 |  |
| Dividend Ratio | 2.78% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 21078912391.46 |  |
| Revenue | 2222381652.45 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.01% | B |
| Profit Margin | 123.25% | A |
| Gross Margin | 48.42% | B |
| Revenue YoY | -6.12% | D |
| Net Profit YoY | 42.60% | B |
| Total Assets YoY | 5.24% | C |
| Net Assets YoY | 6.85% | B |
| Cash Flow Margin | 8.27% | D |
| OCF YoY | -6.12% | D |
| Turnover | 0.06 | E |
| Gearing Ratio | 10.08% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jilin Aodong Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.12%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "42.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.78%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "21078912391.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2222381652.45",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.01%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "123.25%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "48.42%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.12%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "42.60%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.24%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.85%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "8.27%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-6.12%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.08%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.63 | 1/215 | 10.63 | 9.66 | 8.70 |
| PB | 0.67 | 2/215 | 0.80 | 0.75 | 0.70 |
| PS (TTM) | 9.41 | 183/215 | 10.29 | 9.74 | 9.15 |
| Dividend Yield | 2.80% | 40/215 | 2.81% | 2.60% | 2.47% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2024-10-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.52 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000623.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000623.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000623.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000623.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**